Company Overview of Sandoz International GmbH
Sandoz International GmbH develops, produces, and markets generic pharmaceutical products, biotechnological active substances, and anti-infectives in Germany, the United Kingdom, and internationally. It offers antibiotics, generic injectables, oncology injectables, ophthalmic and dermatology products, inhalers and transdermal patches, biotechnological products, cardiovascular medicines, treatments for central nervous system disorders, gastrointestinal medicines, respiratory therapies, hormone therapies, and medications for blood and blood forming organ disorders. The company also offers biosimilars, such as Omnitrope, Binocrit, and Zarzio for treating neutropenia; alimentary tract and metabo...
Key Executives for Sandoz International GmbH
Chairman of the Executive Board and Head of Anti-Infectives
Head of Legal and General Counsel
Country Head of Sandoz Germany & Hexal and Member of Supervisory Board
Compensation as of Fiscal Year 2013.
Sandoz International GmbH Key Developments
Rochon Genova LLP Commences Class Action Against Apotex Inc., Sandoz International GmbH and Sandoz Canada Inc
Oct 28 13
On October 25, 2013, the law firm of Rochon Genova LLP issued a class action on behalf of users of generic versions of diabetes drug ACTOS (pioglitazone hydrochloride) against generic manufacturers and distributors Apotex Inc., Sandoz International GmbH, and Sandoz Canada Incorporated. Pioglitazone, under the brand name ACTOS(R), was approved for sale in Canada in August, 2000 to control blood sugar levels in people with Type 2 (non insulin-dependant) diabetes. A June 2011 study reported to the FDA found a clear link between pioglitazone and increased bladder cancer risk. The risk for bladder cancer was found to be 30% higher among those whose duration of pioglitazone use was 12-24 months and 50% higher among those with greater than 24 months' exposure. Health Canada subsequently commenced a year-long review and, in April 2012, following that review, the product monographs of ACTOS and its generic versions were updated to reflect the increased risk of bladder cancer, but the drugs remain on the market. The class action, filed with the Ontario Superior Court of Justice, alleges, among other things, that the defendants knew or ought to have known that their generic versions of ACTOS, namely APO-Pioglitazone and Sandoz(R) Pioglitazone, materially increase the risks of bladder cancer and failed to disclose those risks in a timely manner and have failed to recall the drug.
Sandoz International GmbH Launches SurepalTM – Simple and Secure Device Innovation for Patients Using Human Growth Hormone (hGH)
Sep 23 13
Sandoz announced the launch of SurePal™, a new delivery device to optimize the simplicity and security of administering Omnitrope® human growth hormone for patients, their physicians and care givers. SurePal has been CE marked in accordance with European Union (EU) laws on medical devices. The device is now available for patients in the United Kingdom and will be launched globally. New device is a Sandoz innovation that will be available exclusively with Omnitrope®, SurePal introduces simple and secure features that bring significant benefits to hGH patients, SurePal represents Sandoz’ latest commitment to hGH patients and the endocrinology community, SurePal has been CE marked in accordance with European Union (EU) laws on medical devices. The device is now available for patients in the United Kingdom and will be launched globally. SurePal is a medical device for Omnitrope with cartridges that require no reconstitution, or priming, and a sliding injection button that requires minimum force to operate. Its safety features include non-interchangeable dose-specific cartridges, a dose memory function that remembers the patient’s daily dose and needle hider to reduce anxiety for patients afraid of needles. The new device has been specially designed by Sandoz to offer enhanced simplicity and security during treatment. In a usability study conducted in 106 patients in Germany and the U.S., 92% of respondents found an injection with SurePal very easy or easy to accomplish.
Shareholder Representative Services L.L.C. Provides Update on Lawsuit Against Sandoz Inc., Sandoz AG and Sandoz International GmbH
Aug 31 13
The U.S. District Court for the Southern District of New York dismissed securities fraud and related claims brought by a provider of Shareholder Representative Services L.L.C. against corporate defendants arising from alleged misrepresentations made by the defendants in connection with a corporate merger. Shareholder Representative Services L.L.C. (SRS) sued the Sandoz Inc., Sandoz AG and Sandoz International GmbH and two officers of Sandoz AG, alleging that a merger agreement executed in connection with a 2010 merger in which Sandoz Inc. purchased Oriel Therapeutics Inc. named SRS as the agent and attorney in fact of the Oriel stockholders. The merger agreement further contemplated that SRS would enforce Sandoz Inc.'s obligation to use 'diligent efforts' to attain certain identified 'milestone events' that would trigger 'milestone payments' under the merger agreement. The complaint further alleged the defendants misrepresented the capabilities of their Aeropharm facility, where certain drug development activities were intended to take place that were essential to achieving the milestone events. SRS alleged that as a result of the defendants' misrepresentations, the Oriel shareholders were induced to sell their Oriel securities at artificially deflated prices. Further, SRS alleged that as a result of Sandoz Inc.'s failure to use diligent efforts to achieve the milestone events, the shareholders were deprived of the milestone payments they would otherwise have received. The district court concluded that SRS did not personally suffer an injury in fact, as required to have standing to assert its claims, but instead sought to raise the injuries and legal rights of the shareholders. SRS had no financial stake in the shareholders' claims and suffered no economic injury as a result of the defendants' actions. Under applicable precedent, SRS's role as agent and attorney in fact of the shareholders did not convert the injuries allegedly suffered by the shareholders into SRS's own injuries. As a result, the court held SRS failed to satisfy Article III's standing requirements and therefore granted the defendants' motion to dismiss.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|